Caribou Biosciences (CRBU)
(Delayed Data from NSDQ)
$2.49 USD
+0.05 (2.05%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $2.48 -0.01 (-0.40%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Caribou Biosciences, Inc. (CRBU) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$16.00 | $30.00 | $3.00 | 555.74% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Caribou Biosciences, Inc. comes to $16.00. The forecasts range from a low of $3.00 to a high of $30.00. The average price target represents an increase of 555.74% from the last closing price of $2.44.
Analyst Price Targets (8 )
Broker Rating
Caribou Biosciences, Inc. currently has an average brokerage recommendation (ABR) of 1.56 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.56 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, six are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 66.67% and 11.11% of all recommendations. A month ago, Strong Buy made up 66.67%, while Buy represented 11.11%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 7 | 7 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 2 | 2 | 2 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.56 | 1.56 | 1.56 | 1.33 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/9/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
6/6/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/4/2024 | H.C. Wainwright & Co. | Robert Burns | Strong Buy | Strong Buy |
6/3/2024 | Evercore Partners | Liisa A Bayko | Strong Buy | Hold |
5/7/2024 | SVB Securities | Mani Foroohar | Strong Buy | Strong Buy |
5/7/2024 | Brookline Capital Markets | Leah R Cann | Strong Buy | Strong Buy |
3/13/2024 | Truist Securities | Asthika S Goonewardene | Strong Buy | Strong Buy |
3/8/2024 | Cantor Fitzgerald & Co | Rick Bienkowski | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.56 |
ABR (Last week) | 1.56 |
# of Recs in ABR | 9 |
Average Target Price | $16.00 |
LT Growth Rate | 14.50% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 252 |
Current Quarter EPS Est: | -0.45 |